Bone News and Research

RSS

Lenalidomide safe for elderly patients with chronic lymphocytic leukemia

The oral medication lenalidomide is safe and well-tolerated for elderly patients with chronic lymphocytic leukemia, a group without a well-defined frontline therapy for their disease, researchers from The University of Texas M. D. Anderson Cancer Center reported today at the 50th annual meeting of the American Society of Hematology.

8 Dec 2008

Kiadis Pharma receives two orphan drug designations for Reviroc

Kiadis Pharma has announced that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc Orphan Drug Designations (ODD) for the treatment of two types of Non-Hodgkin Lymphoma (NHL).

8 Dec 2008

Trial shows safety of pre-transplant expansion of umbilical cord blood stem cells

Taking blood stem cells collected from an umbilical cord into the lab and expanding their number before transplanting them to replace a patient's blood supply is as safe as a standard cord blood transplant, researchers reported at the 50th Annual Meeting of the American Society of Hematology.

8 Dec 2008

Gene therapy used to fight AIDS

The apparent success of a case in which German doctors cured a man of AIDS using a bone marrow transplant comes as no surprise to Gerhard Bauer, a UC Davis stem cell researcher.

8 Dec 2008

Studies examine quality of care for hospitalized sickle cell disease patients

A study assessing the quality of care for patients with sickle cell disease in a variety of hospital settings was presented Saturday, December 6 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

8 Dec 2008

Hematopoietic stem cells found to reproduce more slowly than expected

Investigators from Massachusetts General Hospital (MGH) have found a subpopulation of hematopoietic stem cells, the source of all blood and immune system cells, that reproduce much more slowly than previously anticipated.

8 Dec 2008

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Genentech, Inc. and Biogen Idec have announced that two global Phase III studies in chronic lymphocytic leukemia (CLL), CLL8 and REACH, showed Rituxan (rituximab) plus chemotherapy significantly increased the time patients lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS), when compared to chemotherapy alone.

8 Dec 2008

Effects of stem cell source and patient age on stem cell transplantation outcomes

Two studies examining the effects of stem cell source and patient age on stem cell transplantation outcomes were explored at a press conference on Sunday, December 7 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

8 Dec 2008

Age has no impact on survival after bone marrow transplant

Age alone should not determine whether an older patient with acute myeloid leukemia or myelodysplastic syndrome receives a blood stem cell transplant from a matched donor, researchers of the Center for International Blood and Marrow Transplant Research reported today at the 50th annual meeting of the American Society of Hematology.

8 Dec 2008

Novel therapeutic approaches for various forms of thrombocytopenia

Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of platelets in the blood, were presented December 6 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

8 Dec 2008

Kiadis Pharma announces positive results for ATIR in mismatched bone marrow transplantation

Biopharmaceutical company Kiadis Pharma announces that it has successfully completed treatment of the last patient on its ATIR phase I/II clinical trial.

8 Dec 2008

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Incyte Corporation will present updated results from an ongoing Phase II trial of INCB18424, its selective, orally available Janus kinase (JAK) inhibitor, in patients with myelofibrosis (MF) at the 50th American Society of Hematology (ASH) Annual Meeting.

8 Dec 2008

Promacta (eltrombopag) shown to increase platelet counts and reduce bleeding in chronic immune thrombocytopenic

GlaxoSmithKline has announced positive safety and efficacy results from RAISE (RAndomized placebo- controlled ITP Study with Eltrombopag), a Phase III study of Promacta (eltrombopag) in adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who had received one or more prior ITP therapies.

7 Dec 2008

Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Sanofi-aventis has announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology.

7 Dec 2008

Cartilage transplants used to repair damaged shoulder joints

Rush University Medical Center is the only hospital in Illinois - and one of only a few nationwide - using cartilage transplants to repair damaged shoulder joints.

5 Dec 2008

Breakthrough in sickle cell disease and thalassemia research

Researchers have identified a gene that directly affects the production of a form of hemoglobin that is instrumental in modifying the severity of the inherited blood disorders sickle cell disease and thalassemia.

5 Dec 2008

New method of producing synthetic bone

A method of producing synthetic bone, using techniques normally used to make catalytic converters for cars, is being developed by researchers at WMG at the University of Warwick.

5 Dec 2008

Dormant stem cells for emergencies

Many specialized cells, such as in the skin, intestinal mucosa or blood, have a lifespan of only a few days.

5 Dec 2008

Stem cells derived from bone marrow may offer novel therapeutic option for epidermolysis bullosa

Stem cells derived from bone marrow may serve as a novel therapeutic option to treat a disease called epidermolysis bullosa (EB), a disorder characterized by extraordinarily fragile skin, according to a study prepublished online in Blood, the official journal of the American Society of Hematology.

5 Dec 2008

Better targeted, more cost-effective osteoporosis treatment could soon be a reality worldwide

A new method for determining more accurately at which point someone needs further diagnostic tests, or when immediate treatment is warranted, has been developed by The National Osteoporosis Guideline Group in the UK.

3 Dec 2008

Bone News and Research

Lenalidomide safe for elderly patients with chronic lymphocytic leukemia

Kiadis Pharma receives two orphan drug designations for Reviroc

Trial shows safety of pre-transplant expansion of umbilical cord blood stem cells

Gene therapy used to fight AIDS

Studies examine quality of care for hospitalized sickle cell disease patients

Hematopoietic stem cells found to reproduce more slowly than expected

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Effects of stem cell source and patient age on stem cell transplantation outcomes

Age has no impact on survival after bone marrow transplant

Novel therapeutic approaches for various forms of thrombocytopenia

Kiadis Pharma announces positive results for ATIR in mismatched bone marrow transplantation

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Promacta (eltrombopag) shown to increase platelet counts and reduce bleeding in chronic immune thrombocytopenic

Trial shows Elitek significantly reduces plasma uric acid levels versus Allopurinol in adults with hematologic cancers at risk for tumor Lysis syndrome

Cartilage transplants used to repair damaged shoulder joints

Breakthrough in sickle cell disease and thalassemia research

New method of producing synthetic bone

Dormant stem cells for emergencies

Stem cells derived from bone marrow may offer novel therapeutic option for epidermolysis bullosa

Better targeted, more cost-effective osteoporosis treatment could soon be a reality worldwide

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News